Latest News

Arvelle Therapeutics raises $180m in Series A financing

© 123rf.com/sangoiri


by tg

Swiss newco Arvelle Therapeutics has baged a $180m (€159.1m) series A financing led by LSP. The company licenced the anti-epileptic candidate cenobamate (YKP3089) for $100m (€88.4m) upfront from SK Biopharmaceuticals.

It's one of the largest Series A financings for a European biotech company. A global syndicate of investors led by LSP and including NovaQuest, BRV Capital Management, Andera Partners, and H.I.G. BioHealth Partners supported new company Arvelle Therapeutics with a $180m financing to acquire the exclusive rights from Korean SK Biopharmaceuticals to develop and commercialise cenobamate in Europe. Cenobamate (YKP3089) is a small molecule drug discovered at SK Biopharmaceuticals and further developed at SK Life Science, which has been filed for FDA approval, that is being investigated for the treatment of focal seizures in adult patients. Global trials for adults with partial-onset seizures are ongoing to evaluate Cenobamate’s safety.

Under an exclusive licensing agreement with SK Biopharmaceuticals, CNS specialist Arvelle Therapeutics will develop and commercialise cenobamate in Europe as treatment to prevent focal seizures.  SK Biopharmaceuticals will receive $100m upfront for the commercialisation rights and is eligible to receive up to $430m (€380.3m) in milestones plus royalties on net sales generated in Europe when approved. Arvelle intends to file a marketing authorisation application (MAA) for cenobamate for partial-onset seizures in adult patients based on the data generated from SK Biopharmaceuticals’ global clinical trial programme. Belgian UCB SA already markets Vimpat (lacosamide) for focal seizures.

“We launched Arvelle to bring truly innovative CNS products to patients suffering from serious neurological conditions and cenobamate is the perfect potential first portfolio product,” said Mark Altmeyer, President and CEO of Arvelle. “We believe cenobamate has the potential to be an important anti-epileptic drug treatment option for adult patients suffering from partial-onset seizures.”

Cenobamate’s mode of action is not fully understood, but it is believed to work through two separate mechanisms: enhancing inhibitory currents through positive modulation of GABA-A receptors and decreasing excitatory currents by inhibiting the persistent sodium current.

VTT turn waste into biofuels and chemicals

The process that converts bark, sawdust and forestry waste reduces CO2 emissions by 90% compared to fossil fuels, announced the group...

UK launches new payment model for antimicrobials

A 5-year plan to tackle antimicrobial resistance (AMR) published by the UK government has ambitious goals. Using electronic prescription, it aims at...

AMR: Snipr Biome Aps raises €43m to programme pathogens for death

The company utilizes the natural bacterial CRISPR-based adaptive immune system in a programmable fashion to kill target bacteria based on their...

Staten Biotechnology in $430m deal with Novo Nordisk

Under the agreement, Dutch Staten Biotechnology B.V. and Novo Nordisk A/S will collaborate to co-develop Staten's preclinical dyslipidemia...

Kurma Partners announce closing of Biofund III

Kurma Biofund III, which is backed by cornerstone investors Servier, Bpifrance, and Idinvest, will invest in private biopharmaceutical companies....

Arvelle Therapeutics raises $180m in Series A financing

It's one of the largest Series A financings for a European biotech company. A global syndicate of investors led by LSP and including...

Genfit set to raise $100m in Nasdaq IPO

Proceeds of the dual listing will be used to finance the roll-out of Genfit's lead molecule elafibranor, currently in Phase III testing to treat NASH...